Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$40.85 - $77.67 $224,675 - $427,185
-5,500 Reduced 1.34%
405,517 $17.8 Million
Q1 2022

May 16, 2022

BUY
$59.95 - $92.06 $8.45 Million - $13 Million
140,901 Added 52.16%
411,017 $29.7 Million
Q4 2021

Feb 14, 2022

SELL
$81.07 - $121.29 $22.1 Million - $33.1 Million
-272,816 Reduced 50.25%
270,116 $21.9 Million
Q3 2021

Nov 15, 2021

SELL
$101.99 - $166.36 $5.28 Million - $8.62 Million
-51,800 Reduced 8.71%
542,932 $63.2 Million
Q2 2021

Aug 16, 2021

BUY
$141.6 - $179.06 $11 Million - $14 Million
77,937 Added 15.08%
594,732 $98.6 Million
Q1 2021

May 17, 2021

BUY
$132.81 - $182.18 $9.68 Million - $13.3 Million
72,886 Added 16.42%
516,795 $72.1 Million
Q4 2020

Feb 16, 2021

SELL
$138.17 - $184.34 $2.17 Million - $2.89 Million
-15,700 Reduced 3.42%
443,909 $76.8 Million
Q3 2020

Nov 16, 2020

SELL
$114.09 - $145.51 $4.35 Million - $5.55 Million
-38,155 Reduced 7.67%
459,609 $64 Million
Q2 2020

Aug 14, 2020

SELL
$89.45 - $129.85 $18.7 Million - $27.1 Million
-208,662 Reduced 29.54%
497,764 $59.5 Million
Q1 2020

May 15, 2020

SELL
$70.23 - $144.31 $16.3 Million - $33.6 Million
-232,738 Reduced 24.78%
706,426 $70.6 Million
Q4 2019

Feb 14, 2020

BUY
$76.41 - $117.54 $22.6 Million - $34.7 Million
295,300 Added 45.86%
939,164 $110 Million
Q3 2019

Nov 14, 2019

BUY
$61.52 - $91.1 $39.4 Million - $58.3 Million
640,464 Added 18837.18%
643,864 $55.4 Million
Q1 2019

May 15, 2019

BUY
$35.52 - $62.62 $120,768 - $212,908
3,400 New
3,400 $213,000
Q3 2018

Nov 14, 2018

SELL
$44.22 - $75.47 $150,348 - $256,598
-3,400 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$72.38 - $92.5 $246,091 - $314,500
3,400 New
3,400 $271,000

Others Institutions Holding NVRO

About NEVRO CORP


  • Ticker NVRO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,387,800
  • Market Cap $133M
  • Description
  • Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...
More about NVRO
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.